NLS Pharma和Aexon Labs通过AEX-6xx系列扩展DOXA平台，新一代小分子针对觉醒稳定性、认知和神经保护

• DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs
• Supported by Solid Cash Position and Strategic Funding Outlook

ZURICH, Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders, and Aexon Labs, a biotechnology company advancing next-generation central nervous system ("CNS") therapeutics, today announced the expansion of their DOXA platform with the AEX-6xx series, a new generation of small molecules targeting arousal stability, cognition, and neuroprotection. AEX-635, one of the lead DOXA compounds, also modulates Multidrug Resistance-Associated Protein 1 ("MRP1"), offering a synergistic approach to potentially enhance neuroprotective effects and improve CNS drug bioavailability, especially in oxidative stress-driven conditions such as Parkinson's disease and gliopathies.

Financial Strength and Strategic Outlook

Over the past several months, NLS raised approximately $7 million in equity financing as part of the merger and also secured a $25 million equity line of credit agreement ("ELOC"), bolstering its cash position. These financings, together with ongoing licensing discussions across its assets, NLS and Kadimastem believe that NewCelX will be well-capitalized to fund operations for at least the next 12 months.

The committed ELOC is in place to support upcoming clinical programs, which the company intends to utilize prudently and strategically.